Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

Core Insights - Deerfield Management Company disclosed a significant purchase of Celcuity shares, acquiring 980,470 shares valued at approximately $80.60 million in the fourth quarter of 2026 [1][2] - The total value of Deerfield's position in Celcuity reached $170.95 million at the end of the quarter, reflecting an increase of $134.72 million from the previous quarter, driven by both new purchases and share price appreciation [2] Company Overview - Celcuity Inc. is a biotechnology firm focused on precision oncology, utilizing its CELsignia platform and a pipeline of targeted therapeutics to identify specific cellular drivers of cancer for personalized treatment [5] - The company has a market capitalization of $5.3 billion and reported a net income of -$162.72 million over the trailing twelve months [4] Product and Pipeline - Celcuity's lead drug candidate, Gedatolisib, targets the PI3K and mTOR signaling pathways, which are crucial for cancer growth, by blocking multiple components simultaneously [9] - The FDA has accepted Celcuity's new drug application for Gedatolisib in hormone receptor positive, HER2 negative advanced breast cancer, granting it priority review with a decision date set for July 17, 2026 [10] Market Performance - Celcuity's shares have surged over 1,040% in the past year, significantly outperforming the S&P 500's gain of approximately 19% during the same period [7] - The company is expected to release its upcoming quarterly report soon, and as of September 30, it reported having around $455 million in cash and short-term investments, sufficient to fund operations through the next year [11]